ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 1
4Q19 Earnings Conference Call February 20, 2020 ITGR: 4Q19 Earnings - - PowerPoint PPT Presentation
4Q19 Earnings Conference Call February 20, 2020 ITGR: 4Q19 Earnings - - PowerPoint PPT Presentation
4Q19 Earnings Conference Call February 20, 2020 ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 1 Integer Holdings Corporation Fourth Quarter 2019 Earnings Conference Call 9 a.m. Eastern Time, February 20, 2020 A webcast of
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 2
Integer Holdings Corporation
Fourth Quarter 2019 Earnings Conference Call 9 a.m. Eastern Time, February 20, 2020 Speakers: Joe Dziedzic President and Chief Executive Officer Jason Garland Executive Vice President, Chief Financial Officer Tony Borowicz Senior Vice President, Strategy, Corporate Development & Investor Relations
- A webcast of today’s call can be accessed
in the “Investors” section of the Company’s website: http://investor.integer.net
- To participate on the call, please dial:
- 833-236-5762 (U.S.)
- 647-689-4190 (International)
- The conference ID is 8069250
- An online archive of the broadcast will be
available at the website three hours after the live call, and will be available through Thursday, February 27, 2020, by dialing
- 800-585-8367 (U.S.)
- 416-621-4642 (International)
- The conference ID is 8069250
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 3
Presentation of Financial Information & Forward-Looking Statements
Important Information This presentation contains summarized information concerning Integer Holdings Corporation (the “Company”) and its business,
- perations, financial performance and trends. The historical financial and operating data contained herein reflect the consolidated
results of the Company for the periods indicated. No representation is made that the information in this presentation is complete. For additional financial and business-related information, as well as information regarding business and product line trends, see the Company’s most recent Annual Report on Form 10-K (“Form 10-K”) and Quarterly Reports on Form 10-Q filed with the U.S. Securities and Exchange Commission (the “SEC”), as well other reports filed with the SEC from time-to-time. Such reports are or will be available in the investor relations section of our corporate website (investor.integer.net) and the SEC’s website (www.sec.gov). Non-GAAP Financial Measures. This presentation includes financial information prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) as well as other financial measures referred to as non-GAAP. The non-GAAP financial measures in this presentation, which include adjusted net income, adjusted diluted earnings per share, earnings before interest taxes depreciation and amortization (“EBITDA”), adjusted EBITDA, adjusted sales, and organic growth rates should be considered in addition to, but not as substitutes for, the information prepared in accordance with GAAP. For reconciliations of these non-GAAP financial measures to the most comparable GAAP measures, please refer to the appendix to this presentation and the earnings release associated with this period which can be found in the investor relations section of our corporate website (investor.integer.net). Forward Looking Statements. Some of the statements contained in this presentation whether written or oral may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements relating to future sales, expenses, profitability, cash flows, debt repayments and leverage; expected growth of our business and industry; our ability to execute our business model and our business strategy; our ability to identify trends within our industries and to offer products and services that meet the changing needs of those markets; our ability to repay existing indebtedness; projected capital expenditures; our expected tax rates; and other events, conditions or developments that will or may occur in the future. You can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “see,” “potential” or “continue” or “variations” or the negative of these terms or other comparable terminology. These statements are based on the Company’s current expectations and speak only as of as of the date of this presentation. The Company’s actual results could differ materially from those stated or implied by such forward-looking statements. Except as may be required by law, the Company assumes no obligation to update forward-looking information, including information in this presentation, to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results, financial conditions or prospects.
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 4
Agenda
- Opening Comments
- Strategy Update
- Financial Results
- Product Line Review
- 2020 Outlook
- Question & Answer Period
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 5
Opening Comments
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 6
4Q Financial Results
- +7% sales growth … solid growth in all product lines
- Adj. EBITDA +8%, Adj. EPS +20%
- Debt leverage below 3 times Adjusted EBITDA
Full-Year Financial Results
- +4% sales growth … at low end of original guidance growth rate
- Adj. EBITDA +9%, Adj. EPS +23% … exceeded original guidance
- Paid $117 million debt … exceeded original guidance
Strong 2019 Financial Results …
All product lines posted solid sales growth Achieved two strategic
- bjectives: grew profit
2x sales growth rate and reduced debt leverage to 2.9x
(1) Guidance as provided during 4Q 2018 earnings call on February 21, 2019
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 7
Strategy Update
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 8
Journey to Excellence
Sales Growth versus Prior Year:
*Represents reported change prior to Advanced Surgical and Orthopedic (AS&O) divestiture
(2)% (4)%
2015 2016
2015 2016
Declined Declined >6x
- Integrated $1.7B Lake
Region acquisition
- Spun off Nuvectra
- Challenging customer
relationships
Disruption
* *
5% 7%
2017 2018
2017 2018
Market growth ~1x sales growth 5.6x 3.5x
- New leadership team
- Operational stabilization
- Clear strategy
- Portfolio change
- Multi-year plans
Stabilizing & Building
*
Strategy Financial Objectives
- Sales growth 200 basis
points above market
- Profit growth 2x sales
growth rate
- Debt leverage 2.5x - 3.5x
1 2 3
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 9
Portfolio Strategy Operational Strategy: Strategic Imperatives
How we win in the markets we serve How we achieve excellence in everything we do
Cardio & Vascular Neuromodulation Electrochem Portable Medical
Invest to Grow Protect & Preserve
Cardiac Rhythm Management
Strategy Developed in 2nd half of 2017
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 10
Business Presidents
Payman Khales President Cardio & Vascular February 2018 Joel Becker President, Cardiac Rhythm Management & Neuromodulation April 2019 Carter Houghton President, Electrochem & Power Solutions May 2019 Kirk Thor Chief Human Resources Officer January 2018 Jason Garland Chief Financial Officer October 2018 Joe Flanagan EVP, Quality & Regulatory Affairs 2012 Jen Bolt SVP, Global Operations 2005 Tony Borowicz SVP, Strategy, Business Development, Investor Relations 2002
Functional Leaders
Joe Dziedzic President & CEO July 2017
Leadership Team In Place
Elizabeth Giddens General Counsel and Chief Ethics & Compliance Officer August 2019
6 new leaders in 2018/2019
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 11
Building & Strengthening Culture
Investing in Culture Strategic Imperatives 2018 & 2019 Actions
Building Leadership Capability to Deliver Performance Excellence
Leadership Capability Performance Excellence HR Transformation
- Talent Analytics
- Talent Review / Evaluation
- Selection Process
- Leadership Development
- Succession Planning
- Strategic Workforce Planning
- Associate Engagement
- Performance Management
- Total Rewards
- Organization Effectiveness
- Selection Process
− Structured Interview Training − 430+ Leaders Trained − 350+ Interviews Conducted
- Candidate Assessment
- Individual Development Plans
- Performance Management
− Psychometric Assessment − 70+ Candidates − Baseline for development plans − 40% of Sr. Leaders/Mgrs − 60% of HiPo’s + Successors − HiPo’s + Successors − Key Role Identification − Compensation Differentiation
1 2 3 4
Headcount +8% Dollars spend +13%
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 12
20 LEAN Diagnosis events Over 200 participants 140 Projects/Kaizen events 120 Site leaders trained +50% +190 bps
July 2018 to December 2019
- Adj. EBITDA Margin(1)
LEAN Headcount
All sites trained & initial LEAN Diagnosis executed 20.7% 22.6%
Investing in Manufacturing Excellence and LEAN
2017 2019 2019 2017
(1) Refer to the appendix of this presentation for a reconciliation of Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, and organic growth rates to the most directly comparable GAAP measure
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 13
Multi-year contracts signed in 2019 +10% improvement +40% improvement
Delivering for Customers
~$425 million
Quality(1) On Time Delivery Sales
(1) Quality metric reflects improvement in customer complaints rate
Annual sales 2017 2019 2017 2019
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 14
Portfolio & Product Line Strategy
✓ Divested AS&O … $600 million price; EPS accretive day one ✓ Addressed Portable Medical profitability … “Invest to Grow” ✓ Launched Growth Teams in 4Q18 … Defined strategy
process; own development and oversight of execution
Operational Strategic Imperatives
Strategy Execution … Status
Culture
- Built Leadership
Team
- Aspire to
Excellence
Cost
- LEAN
Deployment
- Operational
Improvements
Customers
- New Sales
Leadership
- Adding
Capabilities
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 15
Debt to Adj. EBITDA Leverage Ratio(1)
Significantly Reduced Debt Leverage
($ in millions)
(1) Leverage Ratio calculated as total principal amount of debt outstanding less Cash and Cash Equivalents divided by trailing 4 quarter Adjusted EBITDA (2) Net Total Debt shown is total principal amount of debt outstanding less Cash and Cash Equivalents
Net Total Debt(2) $1,719 $1,598 $916 $812
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 16
Delivered 67% Adjusted Earnings Per Share Growth
$2.81 $4.68 $3.80
Adjusted Earnings Per Share Up $1.87 +67%
Adjusted EPS(1)
(1) Refer to the appendix of this presentation for a reconciliation of Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, and organic growth rates to the most directly comparable GAAP measure
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 17
Delivering for Investors … Met or Exceeded Guidance(1)
($ in millions)
$255 $275 to to $259 $283 $2.70 $3.35 $4.05 to to to $3.10 $3.80 $4.25
Adjusted Sales Adjusted EBITDA(2) Adjusted EPS
$1,390 $1,175 $1,260 to to to $1,430 $1,200 $1,280
Guidance
Consistently Delivering on Commitments
$1,213 $1,258 $1,462 $1,131 $259 $284 $295 $234 $3.80 $4.68 $3.09 $2.81
With AS&O Without AS&O
(1) Refer to the appendix of this presentation for a reconciliation of Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, and organic growth rates to the most directly comparable GAAP measure (2) Guidance not provided for 2017 Adjusted EBITDA
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 18
2017 2018 2019
Profit Growth 2x Sales Growth Rate in 2019 … and Beyond
($ in millions)
- Adj. EBITDA
$234 $259 $284
Continued Progress … Delivered Adj. EBITDA Growth 2.5x Sales Growth in 2019
- Adj. EBITDA to
sales growth ratio(1)
0.1x 1.5x 2.5x
- Adj. Sales growth
5% 7% 4%
- Adj. EBITDA growth
0.1% 11% 9%
(1) Refer to the appendix of this presentation for a reconciliation of Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, and organic growth rates to the most directly comparable GAAP measure
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 19
Journey to Excellence
Sales Growth versus Prior Year:
(2)% (4)%
2015 2016
5% 7%
2017 2018
2015 2016 2017 2018
Market growth ~1x sales growth 5.6x 3.5x
- New leadership team
- Operational stabilization
- Clear strategy
- Portfolio change
- Multi-year plans
Declined Declined >6x
- Integrated $1.7B Lake
Region acquisition
- Spun off Nuvectra
- Challenging customer
relationships Market growth 2x sales growth 2.9x 2.5x - 3.5x
- Leadership team complete
- Executing strategy, including
bolt-on acquisitions
- Deleveraging
4%
2019 2020
3% - 4%
Disruption Stabilizing & Building Profit Expansion
*Represents reported change prior to AS&O divestiture
* * *
Strategy Financial Objectives Sales growth 200 basis points above market Profit growth 2x sales growth rate Debt leverage 2.5x – 3.5x
1 2 3
Financial Results
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 21 (1) Refer to the appendix of this presentation for a reconciliation of Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, and organic growth rates to the most directly comparable GAAP measure
($ in millions, except per share amounts)
Sales Adjusted EBITDA Adjusted Net Income
$326 $73 $68
4Q19 Adjusted Financial Results(1)
$303 $34 $41
Adjusted EPS
% Growth 7% 8% 20% $1.25 $1.04
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 22
($ in millions, except per share amounts)
Adjusted Sales Adjusted EBITDA Adjusted Net Income
$1,258 $284 $259 $1,213 $124 $154
2019 Adjusted Financial Results(1)
% Growth 4% 9% 24%
(1) Refer to the appendix of this presentation for a reconciliation of Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, and organic growth rates to the most directly comparable GAAP measure
Adjusted EPS
$4.68 $3.80
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 23
($ in millions, except per share amounts)
2019 Adjusted Net Income(1)
$3.80 $0.63 $0.02 $0.17 $0.06 $4.68 Adj. EPS
(1) Refer to the appendix of this presentation for a reconciliation of Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, and organic growth rates to the most directly comparable GAAP measure
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 24
2019 Actual Results Compared to Original Guidance
Debt Payments
(1) Free Cash Flow defined as Cash Flow from Operations less Capital Expenditures (acquisition of property, plant, and equipment (PP&E), net of proceeds from sale of PP&E) (2) Leverage calculated as total principal amount of debt outstanding less Cash and Cash Equivalents divided by Trailing 4 Quarter Adjusted EBITDA (3) 2019 guidance as provided on February 21, 2019
Cash Flow From Ops Free Cash Flow(1) Leverage(2)
($ in millions, except per share amounts)
Original Guidance(3) Actual Actual Actual Actual
$160 - $170 $165 $110 - $120 $117 $105 - $115 $117 2.5x - 3.5x 2.9x
Original Guidance(3) Original Guidance(3) Original Guidance(3)
Memo: Bus Dev $15
Product Line Review
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 26
Cardio & Vascular
Year-over-Year Sales Growth Continues(1)
Trailing 4 Quarters
Integer – Trailing 4 Quarters
(1) Excludes impact from changes in foreign currency exchange rates and US Bio Design Acquisition
Advanced Surgical, Orthopedic & Portable Medical Electrochem (Non-Medical) Cardiac & Neuromodulation
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 27
Offering a full-range of products and services for catheter-based interventional vascular devices and a suite of supply chain solutions to support the development and manufacturing of complex components, sub-assemblies and finished devices
Steerable Sheaths Catheters & Sheaths Guidewires, Stylets & Accessories Introducers
Reported Trailing 4 Quarter Sales
($ in millions)
Quarterly Adjusted Sales Change(1)
Cardio & Vascular
10% 10% 7% 5% 4%
- 4Q19 growth led by a strong increase in peripheral vascular
demand from a customer launching existing program into new geography and market growth. Incremental sales from the signing of a customer contract on existing business fully offset the impact of an end of life electrophysiology program
- Trailing 4 sales quarter driven by strong growth of peripheral
vascular and structural heart, overcoming a ~200 basis points headwind from an end of life electrophysiology program
- Expect 2020 to be mid-single-digit growth as product
launches ramp and the impact of the end of life electrophysiology program lessens
r ts
Y-o-Y% Change
(1) Excludes impact from changes in foreign currency exchange rates and acquisitions
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 28
Providing technology solutions for the active implantable medical device industry by partnering with customers to bring high-quality products to established and emerging markets – from initial concept through high-volume manufacturing
Pulse Generator Components & Assemblies Leads & Lead Components, Adaptors & Assemblies Pulse Generators & External Solutions (Programmers, Chargers, Patient Devices)
Reported Trailing 4 Quarter Sales
($ in millions)
CRM & Neuromodulation
4% 4% 2% (1)% 3%
- 4Q19 growth driven by new and next generation product
launches, underlying strength in existing CRM programs, and a new customer agreement on existing business, partially offset by the Nuvectra Chapter 11 filing
- Trailing 4 quarter sales increase driven by CRM growth due
to higher market demand and the new customer agreement
- n existing business, which was partially offset by slight
neuromodulation decline due to the Nuvectra Chapter 11 filing and market contraction
- Expect slight decline in total for 2020, as double-digit decline
in neuromodulation from Nuvectra bankruptcy offsets low- single-digit growth in CRM
Y-o-Y% Change
(1) Excludes impact from changes in foreign currency exchange rates
Quarterly Adjusted Sales Change(1)
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 29
Orthopedic Implants & Instruments Core Battery Pack Assemblies Li-Ion Battery Packs Electrosurgical Accessories
Reported Trailing 4 Quarter Sales
($ in millions)
Advanced Surgical, Orthopedics & Portable Medical
Offering a broad portfolio of power solutions and technologies to Portable Medical markets and supporting the divested AS&O product line
14% 7% 1% 0% 1%
- 4Q19 sales growth driven by increased end-market demand
for Advanced Surgical and Orthopedic base products
- Trailing 4 quarter sales trend remains relatively flat across all
product lines
- Expect 2020 mid-single-digit growth with accelerating
Portable Medical demand
Y-o-Y% Change
(1) Excludes impact from changes in foreign currency exchange rates
Quarterly Adjusted Sales Change(1)
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 30
Enhancing lives worldwide by providing superior power solutions that enable the success and advancement of our customers’ critical applications
Battery Packs Battery Chargers Battery Cells
Reported Trailing 4 Quarter Sales
($ in millions)
Electrochem
(7)% (8)% (4)% 4% 10%
- 4Q19 growth driven by increased military market
demand and growth in the energy market
- Trailing 4 quarter sales returning to double-digit growth
driven by strong demand in the military market and high- single-digit growth with energy customers
- Expect 2020 high-single-digit growth from new product
launches and increased military and environmental demand
Y-o-Y% Change
(1) Excludes impact from changes in foreign currency exchange rates
Quarterly Adjusted Sales Change(1)
2020 Outlook
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 32
2020 Sales Outlook
($ in millions)
$59 - $79 $1,290 - $1,310 5% - 6% 3% - 4% (2)% % Growth
Nuvectra Fewer Days in 2020
5 to 6% Growth Offset by 2% Headwinds
Growth Headwinds
Sales
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 33
2020 Full-Year Outlook(1)
Adjusted EPS
% Growth 3% - 4% 9% - 13%
Sales
6% - 8%
Adjusted EBITDA
$1,258 $4.68 $1,290 - $1,310 $5.10 - $5.30 $284 $300 - $307
($ in millions, except per share amounts)
(1) Refer to the appendix of this presentation for a reconciliation of Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, and organic growth rates to the most directly comparable GAAP measure
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 34
Debt Payments
(1) Free Cash Flow defined as Cash Flow from Operations less Capital Expenditures (acquisition of property, plant, and equipment (PP&E), net of proceeds from sale of PP&E) (2) Leverage calculated as total principal amount of debt outstanding less Cash and Cash Equivalents divided by Trailing 4 Quarter Adjusted EBITDA, as of end of each year
Cash Flow From Ops Free Cash Flow(1) Leverage(2)
2020 Cash Flow Outlook
$548 $175 - $185 $105 - $125 $90 - $110 $52 - $72
Divestiture Proceeds Accelerated Repayment Required Repayment
$700 $117
CAPEX
$60 - $70
($ in millions, except per share amounts)
Target 2.5x - 3.5x Memo: Bus Dev $15 $10
$44 $48
Summary
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 36
Journey to Excellence
Sales Growth versus Prior Year:
(2)% (4)%
2015 2016
5% 7%
2017 2018
2015 2016 2017 2018
Market growth ~1x sales growth 5.6x 3.5x
- New leadership team
- Operational stabilization
- Clear strategy
- Portfolio change
- Multi-year plans
Declined Declined >6x
- Integrated $1.7B Lake
Region acquisition
- Spun off Nuvectra
- Challenging customer
relationships Market growth 2x sales growth 2.9x 2.5x - 3.5x
- Leadership team complete
- Executing strategy, including
bolt-on acquisitions
- Deleveraging
4%
2019 2020
3% - 4%
Disruption Stabilizing & Building Profit Expansion
*Represents reported growth prior to AS&O divestiture
* * *
200 bps above market 2x sales growth 2.5x – 3.5x
“Excellence in everything we do”
Market + 2%
Sales Growth Rate Expansion Strategic Objectives
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 37
R&D Headcount Sales & Marketing $ Spend Capabilities
Chaska, Plymouth +C&V quick-turn US BioDesign (M&A) +Complex braiding Salem +Laser machining 2017 2020 2017 2020 +30% +25%
Investing in Capabilities for Growth
Inomec (M&A) +Delivery systems, catheters
Investing ~$35 million ‘18-’20
+ERP at 4 sites
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 38
Salem Montevideo Juarez Tijuana South Tijuana North +Site expansion +Site expansion +Site expansion +Build-out +First IPG device manufacturing site in Mexico, FDA approved +IPG manufacturing capacity
Investing in Capacity for Growth
Investing ~$40 Million 2018 to 2020
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 39
Attractive Value Proposition
Financial Objectives Status Integer Strategy
Profit growth 2x sales growth rate Profit
- Strong Leadership Team
2
- Investing to Execute Strategy
4
- Clear Strategy
1
- Delivering Strong Operational
& Financial Results 3
Sales growth 200 bps above market Sales 2.5x – 3.5x adjusted EBITDA Debt Leverage
Earn a valuation premium
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 40
Questions?
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 41
APPENDIX
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 42
4Q19 Adjusted Net Income (1)
($ in millions, except per share amounts)
$1.04 $0.17 $(0.01) $0.05 $0.00 $1.25 Adj. EPS
(1) Refer to the appendix of this presentation for a reconciliation of Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, and organic growth rates to the most directly comparable GAAP measure
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 43
Debt Payments
(1) Free Cash Flow defined as Cash Flow from Operations less Capital Expenditures (acquisition of property, plant, and equipment (PP&E), net of proceeds from sale of PP&E) (2) Leverage calculated as total principal amount of debt
- utstanding less Cash and Cash Equivalents divided by
trailing 4 quarter Adjusted EBITDA (3) 3Q18 Accelerated Repayments totaled $588M; $548M from divestiture proceeds plus $40M from operations
Cash Flow From Ops Free Cash Flow (1)
Accelerated Repayment from Divestiture Proceeds Accelerated Repayment Required Repayment
- Reduced leverage ratio to
2.9 times adjusted EBITDA
- No significant maturities
until 2022; well within covenants
Leverage (2)
$595 $40 $548
(3)
2019 Highlights
Cash Flow & Leverage
($ in millions)
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 44
Adjusted Sales Adjusted EPS
(1) Refer to the appendix of this presentation for a reconciliation of Adjusted Sales and Adjusted EPS to the most directly comparable GAAP measure (2) The quarterly and annual EPS numbers are calculated independently and may not sum to the total (3) Excludes impact of foreign currency reported in other (income)/loss, net Impact of foreign currency reported in other (income)/loss, net Adjusted EPS, as reported
Organic Adjusted EPS(3)
(2)
$265 $313 $305 $303 $280 $285 $301 $292 $315 $314 $304
$(0.05) $(0.01) $0.58 $0.91 $0.98 $0.89 $0.66 $1.01 $1.10 $1.04 $1.00 $1.23 $1.19 $1.26
$326
Historical Financial Results(1)
($ in millions, except per share amounts)
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 45
2020 Full-Year Outlook
($ in millions, except per share amounts)
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 46
Non-GAAP Reconciliation
Income from Continuing Operations and Diluted EPS Reconciliation – QTD
See the Footnotes to this table on page 48 of this presentation ($ in thousands, except per share amounts)
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 47
Non-GAAP Reconciliation
Income from Continuing Operations and Diluted EPS Reconciliation – YTD
See the Footnotes to this table on page 48 of this presentation ($ in thousands, except per share amounts)
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 48
Footnotes to Non-GAAP Reconciliation
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 49
Non-GAAP Reconciliation
4Q19 Income from Continuing Operations and Diluted EPS Reconciliation – Detailed View
($ in thousands, except per share amounts)
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 50
Non-GAAP Reconciliation
YTD Income from Continuing Operations and Diluted EPS Reconciliation – Detailed View
($ in thousands, except per share amounts)
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 51
Non-GAAP Reconciliation
EBITDA and Adjusted EBITDA Reconciliation
($ in thousands)
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 52
Non-GAAP Reconciliation
Organic Sales Growth Rate Reconciliation (% Change)
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 53
12/31/19 Original 12/31/19 As Reported Rate Rate Cash & Cash Equivalents 13 $ $200M Revolver [Due 2022]
- $
L + 325 L + 200 TLA [Due 2022] 267 $ L + 325 L + 200 TLB [Due 2022] 558 $ L + 425 L + 250 Total Principal Amount of Debt Outstanding 825 $ Deferred Fees and OID (10) $ Total Debt (Principal Amount of Debt Outstanding Less Deferred Fees and Discounts) 815 $ Net Total Debt (Principal Amount of Debt Outstanding Less Cash) 812 $ Continuing Operations Statistics Trailing 4 Quarter Adjusted EBITDA 284 $ Trailing 4 Quarter Cash Interest Expense 45 $ Trailing 4 Quarter Capital Expenditures 48 $ Credit Statistics Net Total Debt / Trailing 4 Quarter Adjusted EBITDA 2.9x Trailing 4 Quarter Adjusted EBITDA / Cash Interest Expense 6.3x
(1) (1) Principal amount of debt outstanding, not reduced for unamortized discount and debt issuance costs (2) Leverage calculated as total principal amount of debt outstanding less Cash and Cash Equivalents divided by trailing 4 quarter Adjusted EBITDA (2)
Capitalization
($ in millions)
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 54
Non-GAAP Reconciliation for Fiscal Year 2017 & 2016
GAAP income from continuing operations to Adj. EBITDA from continuing operations
($ in thousands)
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 55
Non-GAAP Reconciliation for Fiscal Year 2017 & 2016
GAAP income from total operations to Adj. EBITDA from total operations
($ in thousands)
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 56
Non-GAAP Reconciliation for Fiscal Year 2017
YTD Income from Continuing Operations and Diluted EPS Reconciliation – Detailed View
($ in thousands, except per share amounts)
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 57
Non-GAAP Reconciliation for Fiscal Year 2017
GAAP net income and diluted EPS to adjusted amounts
($ in thousands, except per share amounts)
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 58
Non-GAAP Reconciliation for Fiscal Year 2017
GAAP net income and diluted EPS to adjusted amounts – detailed view
($ in thousands, except per share amounts)
(a) (a)
ITGR: 4Q19 Earnings Conference Call / February 20, 2020 / Page 59
Contact Information
Tony Borowicz
SVP, Strategy, Business Development & Investor Relations
Integer
Tony.Borowicz@Integer.net www.integer.net
(O) 716.759.5809